XLV250110P142000
- 1.83
- -2.92-61.47%
The Health Care Select Sector SPDR® Fund Newsroom
Wall Street's Tough Week Pushes S&P 500 Into Negative Territory for the New Year
CMS Proposes 4.33% Increase for Medicare Advantage Plans
SpringWorks Therapeutics Jumps Amid Takeover Speculation
Catalyst Watch: Bank Earnings, Oil Updates, Powerhouse Conferences in Retail and Healthcare
BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst
Lilly Signs Licensing Deal With Mediar for IPF Drug
"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times
Wall Street Tumbles On Blowout Payrolls, Oil Rallies To $76, US Dollar Hits 26-Month Highs: What's Driving Markets Friday?
UnitedHealth Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
AbbVie Unusual Options Activity For January 10
Sector Update: Health Care Stocks Decline Premarket Friday
HIMS Downgraded, Agilon Upgraded at Citi in 2025 Health Tech Review
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
Pfizer Says Its Sasanlimab In Combination With Bacillus Calmette-Guérin (BCG) Improves Event-Free Survival In Patients With BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To...
Morgan Stanley's outlook for the top ten investment trends in 2025: the revival of nuclear energy, the AI revolution in the financial Industry, quantum computing, oral weight loss medications...
Morgan Stanley pointed out that historically, popular themes with strong profit momentum tend to have a strong sustainability, such as AI, defense spending, and obesity drugs; negative prices and quantum computing are expected to emerge as new investment hotspots.
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report